Sabby Management’s Crescent Biopharma CBIO Stock Holding History

Sabby Management’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-516	Closed	-$838K	–	158
2018 Q1	$838K	Buy	+516	New	+$1.07M	0.1%	75

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management's CBIO Position: Q2 2018 in Review

Sabby Management sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 516 shares — an estimated $838K sold.

Sabby Management first reported a position in CBIO in Q1 2018 and held it in 1 quarter. The position peaked at $838K in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

Sabby Management reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 516 Crescent Biopharma shares in Q2 2018, an estimated $838K.
Sabby Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 1 quarter.
Sabby Management's Crescent Biopharma position peaked at $838K in Q1 2018.
84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.